Obsidian Therapeutics shared its third-quarter results, showing a 67% success rate in its melanoma study and strong cash reserves.

Nov 12, 2026, 4:53 PM ETResultsRead the original at SEC EDGAR

Good for OBX

Obsidian reported a 67% response rate among 15 patients with advanced melanoma and cash expected to last into the second half of 2028. The small, uncontrolled study still needs confirmation, but the reported results support a favorable read.

OBX · Obsidian Therapeutics, Inc.

AI read · Good for OBX

The AI's read

The treatment results suggest amsoki-cel may help people with advanced melanoma, and Obsidian reported cash to support its work into the second half of 2028. The study included only 15 people and had no comparison group, so more results are needed. Enrollment continues, with the next main results expected by the end of 2027.

Get alerts for OBX

Follow Obsidian Therapeutics, Inc. (OBX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OBX

Free on the App Store and Google Play, or on the web.